Introduction
In Japan, subtotal or total gastrectomy, plus D2 lymph node dissection, is commonly performed for advanced gastric cancer, as well as in some patients with early cancer. For patients with advanced cancer, postoperative adjuvant chemotherapy has been given routinely. Many of these patients have survived for long periods, and second primary cancers have been detected in some of these long survivors [1] . The incidence of a second malignancy occurring in the colon is particularly high after gastrectomy for stomach cancer, as reported by Lundegardh et al. [2] .
In breast cancer patients, Koyama et al. [3] reported that the risk of a second malignancy increased significantly after chemotherapy. Boivin et al. [4] reported that chemotherapy increased the risk of cancer in bone and soft tissue. In stomach cancer patients, however, it is unclear whether chemotherapy increases the risk of a second malignancy.
We evaluated the risk of a second malignancy in patients with stomach cancer who underwent gastrectomy with or without adjuvant chemotherapy in the past 20 years.
Patients and methods
A total of 1961 patients underwent gastrectomy for stomach cancer between 1978 and 1992 at Osaka Medical Center for Cancer and Cardiovascular Diseases. They were followed-up after the operation and examined for a second malignancy. The end of the follow-up period was the end of December 1994. The aver- age follow-up period was 7.99 years. Thirty-six patients who were diagnosed with malignancies within 2 months of the treatment for stomach cancer were excluded from this study because of the possibility of simultaneous cancer. Accordingly, 1925 patients were selected for this study: 1114 patients who underwent surgery alone (group A), and 811 patients who underwent surgery and received chemotherapy (group B). In group B, 5-fluorouracil, tegafur and uracil (UFT), FT 207, and/or mitomycin C (MMC) were administered to 300, 159, 152, and/or 324 patients, respectively ( Table 1) .
The observed incidence of second malignancies (O) was compared with the expected incidence (E) of malignancies, which was calculated by person-year method [5] , using data from the Cancer Registry in Osaka. To obtain the number of expected second primary cancers, site-specific, sex, 5-year age group, and 5-year calendar period incidence rates for each cancer among Osaka residents were applied to the appropriate personyear at risk. The ratio of the observed to the expected (O/E) cases indicates the relative risk (RR) of the malignancy.
For statistical analyses, either the 2 test or Student's t-test was used. Statistical tests of the ratio of observedto-expected numbers were based on the assumption that the observed numbers followed a Poisson distribution. Results were considered statistically significant if the 95% confidence interval (CI) did not contain 1.0.
Results
Second malignancies were detected in 127 patients during the follow-up period (97 men and 30 women). In group A, 73 patients had a second malignancy, and in group B, 44 patients had a second malignancy. The relative risks of a second malignancy in all patients, group A patients, and group B patients were 1.02, 1.05, and 1.02, respectively. There was no significant difference between the groups in these relative risks ( Table  2) .
The main sites of the second primary tumor were the lung (in 26 patients), the liver (n ϭ 21), the colon (n ϭ 18), the rectum (n ϭ 14), the esophagus (n ϭ 8), and the pancreas (n ϭ 4). Second primary cancers in digestive organs accounted for 56.7% of all second malignancies (72/127). The relative risk of each second malignancy was 1.94 in the rectum, 1.65 in the colon, 1.61 in the esophagus, 0.92 in the liver, 0.63 in the pancreas, and 0.95 in the lung ( Table 3 ). The relative risk of a second primary cancer in the rectum was significantly high (P Ͻ 0.05 vs).
In group A, the relative risks of a second primary cancer in the digestive and respiratory organs were 0.83 (95% confidence interval [CI], 0.61-1.11) and 0.78 (95% CI, 0.41-1.33) (Table 4) , while in group B, these relative risks were 0.55 (95% CI, 0.33-0.86) and 1.03 (95% CI, 0.52-1.85) ( Table 5 ). The relative risks of a second primary cancer in the colon and rectum were 1.49 (95% CI, 0.68-2.83) and 2.47 (95% CI, 1.18-4.55) in group A, and 1.59 (95% CI, 0.58-3.47) and 1.21 (95% CI, 0.24-3.54) in group B.
According to the anticancer agents used for adjuvant chemotherapy, the relative risks were 0.79 for 5-fluorouracil (5-FU), 1.01 for tegafur and uracil (UFT), 1.06 for FT207, and 0.90 for mitomycin C (MMC) ( Table 6 ).
Discussion
Although many trials of adjuvant chemotherapy for gastric cancer have been carried out in Japan, most have been unable to show the effectiveness of the treatment. On the other hand, some authors have reported that the risk of a second malignancy after chemotherapy was high, and the second malignancy was an important factor in decreasing the survival rate [6, 7] . The risk of a second malignancy after treatment for stomach cancer has been reported as being increased [8, 9] , unchanged [7, 10] , and decreased [11, 12] . We have also reported that the risk of rectal cancer was high after treatment for stomach cancer [13] . In the present series, the risk of rectal cancer in group A patients was also significantly higher than the unity. Pawlish et al. [14] reported that radiation therapy for prostate cancer was a cause of second primary cancer in the bladder. Lambert et al. [15] suspected that chemotherapy and radiation treatment for Hodgkin's disease caused pancreatic cancer. Other authors [16, 17] suspected that chemotherapy for Hodgkin's disease caused leukemia.
In our study, the relative risk of a second malignancy in patients who underwent surgery and received chemotherapy (1.02) was not significantly higher than that in patients who received no chemotherapy. In particular, in group B, the risks of a second malignancy in the digestive organs were lower than those in group A. According to the anticancer agents used, the relative risks for 5-FU (0.79) and MMC (0.90) were low; however, the differences between groups according to anticancer agent used were not significant.
In another study of second malignancies [13] , rectal cancer and colon cancer as second malignancies occurred within a short period after treatment for stomach cancer. We surmise that these second malignancies were metachronous multiple cancers; also, the growth of these cancers may have been influenced by the surgery and chemotherapy.
The present study was a retrospective study of patients who underwent surgery alone or surgery plus chemotherapy with various regimens. In further studies, all protocols should include a follow-up for second malignancy in their designs.
